BioAv Cancer Research Results
BioAv, bioavailability: Click to Expand ⟱
| Source: |
| Type: measurement |
Bioavailability (usually in %) absorbed by the body.
|
Park, Parkinson's Disease (PD): Click to Expand ⟱
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms, and is due to the degeneration of dopaminergic neurons. It is multifactorial, caused by genetic and environmental factors and currently has no definitive cure.
-CoQ10 deficiency was observed at a higher frequency in Parkinson's disease
|
Scientific Papers found: Click to Expand⟱
| - |
Review, |
Stroke, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
*neuroP↑, *antiOx↑, *Inflam↓, *BioAv↝, *BioAv↑, *Half-Life↝, *TLR4↓, *NF-kB↓, *iNOS↓, *COX2↓, *TNF-α↓, *12LOX↓, *NLRP3↓, *ROS↓, *IL1β↓, *IL6↓, *GSK‐3β↓, *NRF2↑, *BBB↑, *SOD↑, *GPx↑, *MDA↓,
| - |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*memory↑, *cognitive↑, *ROS↓, *Inflam↓, *motorD↑, *toxicity↓, *TRPV3↑, *other↓, *antiOx↑, *LDL↓, *COX2↓, *PPARα↑, *NO↓, *AChE↓, *eff↑, *SOD↑, *Catalase↑, *neuroP↑, *BioAv↝, *BBB↑, *BioAv↑,
| - |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
- |
Review, |
IBD, |
NA |
|
|
|
*Aβ↓, *neuroP↑, *cardioP↑, *GastroP↑, *RenoP↑, *hepatoP↑, *Obesity↓, *Bacteria↓, *BioAv↑, *BioAv↑, *BioAv↑, *ROS↓, *GutMicro↑, *IBI↑, *MCT1↓, *NF-kB↓, *DNMT1↓,
| - |
Review, |
Var, |
NA |
|
|
|
- |
Review, |
Stroke, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*antiOx↑, *Inflam↓, *hepatoP↑, *neuroP↑, *BioAv↓, *cardioP↑, *lipidLev↓, *RenoP↑, *TNF-α↓, *IL2↓, *PI3K↓, *Akt↓, *ROS↓, *cognitive↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, VEGF↓, p‑STAT3↓, TumMeta↓, TumCP↓, eff↑, eff↑, IL1β↓, IL6↓, NF-kB↓, ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, ER Stress↑, Ca+2↑, TET1↑, Let-7↑, Twist↓, EMT↓, TumCCA↑, Casp3↑, Casp9↑, BAX↑, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓, SHP1↑, N-cadherin↓, E-cadherin↑, UPR↑, PERK↑, ATF4↑, eIF2α↑, RadioS↑, NOTCH1↑, NRF2↓, BioAv↑, eff↑,
| - |
Review, |
Nor, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*antiOx↑, *ROS↓, *BioAv↝, *Half-Life↑, *BioAv↓, *BioAv↑, *cardioP↑, *neuroP↑, *H2O2↓, *VitC↑, *VitE↑, *GPx↑, *GSH↑, *MPO↓, *GSTs↓, *SOD↑, *NF-kB↓, *IL1β↓, *IL6↓, *IL10↑, *MAPK↓, *Akt↓, *COX2↓, *TNF-α↓, *TGF-β1↑, *NO↓, *GSR↑, *NRF2↑, *HO-1↑, *TAC↑, *Inflam↓, *BBB↑, *neuroP↑, *memory↑,
| - |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
- |
Review, |
Diabetic, |
NA |
|
|
|
*AntiDiabetic↑, *AMPK↑, *glyC↓, *ROS↓, *cardioP↑, *neuroP↑, *Half-Life↝, *toxicity↝, *BioAv↑, *glucose↓, *AGEs↓, AntiCan↑, Risk↓, TumCP↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, pRB↓, p27↓, mTOR↓, Casp↑, ROS↑, MMP↓, ChemoSen↑, *hepatoP↑, *CRM↑, *Insulin↓,
| - |
Review, |
Nor, |
NA |
|
|
|
- |
NA, |
AD, |
NA |
|
|
|
- |
NA, |
Diabetic, |
NA |
|
|
|
- |
NA, |
Stroke, |
NA |
|
|
|
- |
NA, |
LiverDam, |
NA |
|
|
|
- |
NA, |
Park, |
NA |
|
|
|
*mtDam↓, *BioAv↝, *BioAv↑, *OS↑, *eff↑, *eff↑, *cognitive↑, *DNAdam↓, *SIRT1↑, *cardioP↑, *ROS↓, *Dose↝, *BioAv↑, *hepatoP↑, *eff↑, *BG↓, *creat↓,
| - |
Review, |
Park, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
*hepatoP↑, *Inflam↓, *neuroP↑, *antiOx↑, *angioG↑, *cardioP↑, *BioAv↑, *P450↓, *eff↑, *BioAv↑, E-cadherin↓, ER(estro)↓, MMP2↓, MMP9↓, VEGF↓, cMyc↓, BAX↑, P53↑, TumCG↓, OS↑, *cognitive↑, *GSK‐3β↓, *GSH↑, *Casp3↓, *Casp9↓, *Cyt‑c↓, *lipid-P↓, *motorD↑, *AChE↓, *memory↑, *cardioP↑, *ROS↓, *PPARγ↑, *ALAT↓, *AST↓, *ALP↓, *AMPK↑, *5HT↑, *SIRT1↑, *eff↑,
| - |
Review, |
Nor, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
- |
Review, |
Park, |
NA |
|
|
|
*ROS↓, *Inflam↓, TumCG↓, *neuroP↑, *cardioP↑, *LDL↓, *BioAv↝, *BioAv↓, *BioAv↑, *SIRT1↑, *mTOR↑, *BDNF↑, *cognitive↑,
| - |
Review, |
Park, |
NA |
|
|
|
- |
Review, |
AD, |
NA |
|
|
|
*Inflam↓, *antiOx↓, *neuroP↑, *p‑tau↓, *Aβ↓, *eff↑, *BioAv↓, *BioAv↑, *GSH↑, *SOD↑, *lipid-P↓, *Catalase↑, *GSR↑, *GPx↑, *ROS↓, *NRF2↑, *GutMicro↑, *Risk↓, *BBB↓, *NLRP3↓, *MAOA↓,
Showing Research Papers: 1 to 10 of 10
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 10
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
NRF2↓, 1, ROS↑, 2,
Mitochondria & Bioenergetics ⓘ
MMP↓, 2,
Core Metabolism/Glycolysis ⓘ
cMyc↓, 1, GlucoseCon↓, 1, Glycolysis↓, 1, HK2↓, 1, lactateProd↓, 1,
Cell Death ⓘ
Apoptosis↑, 2, BAX↑, 2, Casp↑, 1, Casp3↑, 1, Casp9↑, 1, Cyt‑c↑, 1, hTERT/TERT↓, 1, p27↓, 1,
Transcription & Epigenetics ⓘ
pRB↓, 1,
Protein Folding & ER Stress ⓘ
eIF2α↑, 1, ER Stress↑, 1, PERK↑, 1, UPR↑, 1,
DNA Damage & Repair ⓘ
P53↑, 1,
Cell Cycle & Senescence ⓘ
cycD1/CCND1↓, 2, TumCCA↑, 2,
Proliferation, Differentiation & Cell State ⓘ
EMT↓, 1, Let-7↑, 1, mTOR↓, 1, NOTCH1↑, 1, SHP1↑, 1, p‑STAT3↓, 1, TumCG↓, 2,
Migration ⓘ
Ca+2↑, 1, E-cadherin↓, 1, E-cadherin↑, 1, MMP2↓, 1, MMP9↓, 1, N-cadherin↓, 1, TET1↑, 1, TumCP↓, 2, TumMeta↓, 1, Twist↓, 1,
Angiogenesis & Vasculature ⓘ
ATF4↑, 1, VEGF↓, 2,
Immune & Inflammatory Signaling ⓘ
IL1β↓, 1, IL6↓, 1, NF-kB↓, 1,
Hormonal & Nuclear Receptors ⓘ
ER(estro)↓, 1,
Drug Metabolism & Resistance ⓘ
BioAv↑, 1, ChemoSen↑, 1, eff↑, 4, RadioS↑, 1,
Clinical Biomarkers ⓘ
hTERT/TERT↓, 1, IL6↓, 1,
Functional Outcomes ⓘ
AntiCan↑, 1, OS↑, 1, Risk↓, 1,
Total Targets: 56
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress ⓘ
antiOx↓, 1, antiOx↑, 5, Catalase↑, 2, GPx↑, 3, GSH↑, 3, GSR↑, 2, GSTs↓, 1, H2O2↓, 1, HO-1↑, 1, lipid-P↓, 2, MDA↓, 1, MPO↓, 1, NRF2↑, 3, ROS↓, 10, SOD↑, 4, TAC↑, 1, VitC↑, 1, VitE↑, 1,
Mitochondria & Bioenergetics ⓘ
Insulin↓, 1, mtDam↓, 1,
Core Metabolism/Glycolysis ⓘ
12LOX↓, 1, ALAT↓, 1, AMPK↑, 2, CRM↑, 1, glucose↓, 1, glyC↓, 1, LDL↓, 2, lipidLev↓, 1, PPARα↑, 1, PPARγ↑, 1, SIRT1↑, 3,
Cell Death ⓘ
Akt↓, 2, Casp3↓, 1, Casp9↓, 1, Cyt‑c↓, 1, iNOS↓, 1, MAPK↓, 1, MCT1↓, 1,
Kinase & Signal Transduction ⓘ
TRPV3↑, 1,
Transcription & Epigenetics ⓘ
other↓, 1,
DNA Damage & Repair ⓘ
DNAdam↓, 1, DNMT1↓, 1,
Proliferation, Differentiation & Cell State ⓘ
GSK‐3β↓, 2, mTOR↑, 1, PI3K↓, 1,
Migration ⓘ
TGF-β1↑, 1,
Angiogenesis & Vasculature ⓘ
angioG↑, 1, NO↓, 2,
Barriers & Transport ⓘ
BBB↓, 1, BBB↑, 3, GastroP↑, 1, IBI↑, 1,
Immune & Inflammatory Signaling ⓘ
COX2↓, 3, IL10↑, 1, IL1β↓, 2, IL2↓, 1, IL6↓, 2, Inflam↓, 7, NF-kB↓, 3, TLR4↓, 1, TNF-α↓, 3,
Synaptic & Neurotransmission ⓘ
5HT↑, 1, AChE↓, 2, BDNF↑, 1, MAOA↓, 1, p‑tau↓, 1,
Protein Aggregation ⓘ
AGEs↓, 1, Aβ↓, 2, NLRP3↓, 2,
Drug Metabolism & Resistance ⓘ
BioAv↓, 4, BioAv↑, 13, BioAv↝, 5, Dose↝, 1, eff↑, 7, Half-Life↑, 1, Half-Life↝, 2, P450↓, 1,
Clinical Biomarkers ⓘ
ALAT↓, 1, ALP↓, 1, AST↓, 1, BG↓, 1, creat↓, 1, GutMicro↑, 2, IL6↓, 2,
Functional Outcomes ⓘ
AntiDiabetic↑, 1, cardioP↑, 8, cognitive↑, 5, hepatoP↑, 5, memory↑, 3, motorD↑, 2, neuroP↑, 10, Obesity↓, 1, OS↑, 1, RenoP↑, 2, Risk↓, 1, toxicity↓, 1, toxicity↝, 1,
Infection & Microbiome ⓘ
Bacteria↓, 1,
Total Targets: 98
Scientific Paper Hit Count for: BioAv, bioavailability
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:75 Cells:% prod#:% Target#:792 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid
Home Page